²»Á¼Ñо¿Ëù

Partnership to build a platform for the development of safer and more efficient genetic engineering of human cells for cell therap...

²»Á¼Ñо¿Ëù received a gold award for its participation in the Green Impact awards for sustainability.

BlueRock Therapeutics and ²»Á¼Ñо¿Ëù announce collaboration and option agreement for the discovery & manufacture of regulatory T cell...

In this episode of the SynBioBeta podcast, ²»Á¼Ñо¿Ëù CEO Mark Kotter discusses the influence synthetic biology is having on the futu...

²»Á¼Ñо¿Ëù secures foundational United States patent for opti-ox, its cell programming technology that uses genomic safe harbour site...

²»Á¼Ñо¿Ëù's President and COO named as one of the 20 women reshaping biopharma R&D in 2023 report.

An article on synbio in the Summer 2023 issue of Science in Parliament magazine. Authored by our founder and CEO Mark Kotter.

²»Á¼Ñо¿Ëù launches two new human cell disease models to advance discovery and development of treatments for Duchenne muscular dystro...